First Oral PCSK9 Inhibitor Laroprovstat shows Up to 80 Percent LDL Reduction in Phase 1 Trial

Sweden: Laroprovstat, the first oral small-molecule PCSK9 inhibitor under clinical development, demonstrated substantial LDL cholesterol–lowering effects in a phase 1 study involving treatment-naive...